1. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021 Sep 14:S1473-3099(21)00485-0.
2. Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023 Jan 28;401(10373):281–93.
3. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med 2022; 386: 509–20.
4. Khoo SH, FitzGerald R, Saunders G, et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Infect Dis 2022; published online Oct 19. https://doi.org/10.1016/ S1473-3099(22)00644-2.
5. Pfizer. Pfizer’s novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 epic-hr study. 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate
6. ClinicalTrial. A Study of PF-07321332/Ritonavir in Nonhospitalized High Risk Adult Participants With COVID-19. 2021. https://clinicaltrials.gov/ct2/show/NCT04960202
7. Hammond J, Leister-Tebbe H, Gardner A, et al; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022 Feb 16. doi: 10.1056/NEJMoa2118542
8. Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int. J. Infect. Dis. 2021;102:501–8.
9. World Health Organization. Clinical management of COVID-19. WHO. 2023. https://iris.who.int/bitstream/handle/10665/372288/WHO-2019-nCoV-clinical-2023.2-eng.pdf?sequence=1
10. Centre for Disease Control, Taiwan. Avigan Tablet Package Insert. CDC Taiwan, 2017. https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw
11. Informatorium Obat COVID-19 di Indonesia. Badan Pengawas Obat dan Makanan Republik Indonesia. 2022. https://standarobat.pom.go.id/site/product/book/detail/informatorium-obat-covid-19-di-indonesia-edisi-4
12. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. Frontiers in Pharmacology. 2021;12:683296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443786/
13. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 10.1016/j.eng.2020.03.007.
14. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman Tatalaksana COVID-19 Edisi 4. 2022 Januari.
15. U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir, US FDA, 2021. https://www.fda.gov/media/155054/download
16. U.S. Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for PaxlovidTM, US FDA, 2021. https://www.fda.gov/media/155050/download
17. Medscape. Acetaminophen. 2023. https://reference.medscape.com/drug/tylenol-acetaminophen-343346
18. Medscape. Pediatric Acetaminophen Dosing. 2020. https://emedicine.medscape.com/article/2172407-overview
Facebook 
Masuk dengan Email
